DOCSLIB.ORG

Zoster Vaccine: Current Status and Future Prospects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zoster Vaccine: Current Status and Future Prospects ADULT VACCINATION in 2010 American Geriatrics Society 2010 Annual Meeting Zoster Vaccine: Current Status and Future Prospects Michael N. Oxman, M.D. Professor of Medicine and Pathology University of California, San Diego Study Chairman, VA Cooperative Study #403: “The Shingles Prevention Study” DISCLOSURE: Michael N. Oxman, MD • No Conflict of Interest • VA Cooperative Study #403: “The Shingles Prevention Study” and its Substudies, of which Dr. Oxman is National Chairman, has been supported, in part, by grants from Merck and Company, Inc. to the VA Cooperative Studies Program, the VA San Diego Medical Research Foundation, and the VA Connecticut Research and Education Foundation • Dr. Oxman will discuss off-label uses of zoster vaccine and clearly indicate that these are off- label uses We Now Have An Effective Vaccine Against Herpes Zoster • The Same Live Attenuated Dr. Michiaki Takahashi Oka/Merck Strain of VZV Used in the Varicella Vaccine Currently Licensed in the US to Prevent Chickenpox • The Minimum Potency of the Zoster Vaccine was at least 14 Times Greater than that of Varicella Vaccine [Median = 24,600 PFU (19K-60k)] VA Cooperative Study #403: The Shingles Prevention Study Demonstrated the Efficacy of Zoster Vaccine Vaccine Efficacy for the Herpes Zoster BOI Efficacy 61.1% 65.5% 55.4% (95% CI) (51.1- 69.1) (51.5 - 75.5) (39.9 - 66.9) 8 7.78 7 6 5 5.68 4 4.33 3 3.47 2 2.21 Burden of Illness Score Illness of Burden 1 1.50 0 All Subjects Age 60–69 ≥70 n 19,247 19,254 10,356 10,370 8891 8884 Placebo Vaccine Success required a VEBOI point estimate of ≥ 47% and a lower bound of the 95 percent confidence interval >25% Zoster vaccine reduced HZ Pain Interference with ADL by ~66% (Schmader et al.), providing further evidence that the HZ BOI is a valid measure of the total adverse impact of HZ on a population of older persons ZOSTER VACCINE EFFICACY FOR HZ BOI AND INTERFERENCE ENDPOINTS HZ Burden of Illness (BOI) Score ZBPI - ADL Interference AUC ZIQ - ADL Inteference AUC 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Relative Vaccine Efficacy (1-Vaccine/Placebo) Vaccine Efficacy for the Incidence of PHN Efficacy 66.5% 65.7% 66.8% (95% CI) (47.5 - 79.2) (20.4 - 86.7) (43.3 - 81.3) 2.5 2.0 2.13 1.5 1.38 1.0 Incidence of of PHN Incidence 0.74 0.71 (per 1000 person years) person 1000 (per 0.5 0.46 0.26 0 All Subjects Age 60–69 ≥70 n 19,247 19,254 10,356 10,370 8891 8884 Placebo Vaccine Success required a VEPHN point estimate of ≥ 62% and a lower bound of the 95 percent confidence interval >25% Vaccine Efficacy for the Incidence of Herpes Zoster Efficacy 51.3% 63.9% 37.6% (95% CI) (44.2 - 57.6) ((55.5 - 70.9)) (25.0 - 48.1) 14 12 11.5 10 11.1 10.7 8 7.2 6 5.4 4 3.9 (per 1000 person years) person 1000 (per Incidence of of zoster herpes Incidence 2 0 All Subjects Age 60–69 ≥70 n 19,247 19,254 10,356 10,370 8891 8884 Placebo Vaccine Oxman MN et al. N Engl J Med. 2005;352:2271-2284 Summary • Zoster vaccine maintains its efficacy regardless of the age of the subject – The effect in “younger” subjects is mediated mostly by preventing HZ – The effect in “older” subjects is mediated mostly by attenuating HZ Zoster vaccine was shown to be safe and well tolerated (Oxman MN et al. N Engl J Med 2005; 352:2271-2284; Simberkoff et al. Annals Internal Medicine 2010; 152: 545-552.) Safety: Mortality and SAE from Day of Vaccination to End of Study Risk Zoster Events Among Placebo Difference Vaccine All Subjects n (%) (ZV minus P) n (%) Mortality: Whole Cohort 793 (4.1%) 795 (4.1%) 0.01 (-1.2, 1.2) Age 60-69 years 218 (2.1%) 246 (2.4%) -0.80 (-2.0, 0.4) Age ≥70 years 575 (6.5%) 549 (6.2%) 0.95 (-1.2, 3.1) Possibly-related 2 (<0.1%) 3 (<0.1%) NC SAE Hospitalization† 1137 (34.0%) 1115 (34.1%) 0.1 (-8.8, 9.0) HZ-related 5 (0.2%) 6 (0.2%) -0.1 (-0.7, 0.5) † in AE Substudy Oxman M et al. N Engl J Med. 2005; 352:2271-2284; Table 4 Safety: SAE and Rashes (Day of Vaccination to Day 42 Post-Vaccination) Subjects with 1 or Zoster Placebo Risk Difference more: Vaccine (95% CI) SAE 255 (1.4%) 254 (1.4%) 0.01% (-0.2%, 0.3%) Varicella-like rash at 20 (0.1%) 7 (0.04%) 0.07% (0.02%, 0.13%)* the injection site Varicella-like rash 18 (0.1%) 14 (0.1%) 0.02% (-0.04%, 0.09%) not at injection site HZ-like rash 17 (0.1%) 36 (0.2%) -0.10% (-0.18%, -0.03%)* Rash unrelated to 595 (3.2%) 620 (3.3%) -0.13 (-0.49%, 0.23%) HZ Evaluable Case of 7 (0.04%) 24 (0.1%) -0.09% (-0.16%, -0.03%)* HZ * p<0.05 Oxman M et al. N Engl J Med. 2005;352:2271-2284; –Table 4 Safety: AE Substudy – Injection Site AE Day of Vaccination to Day 42 Post-Vaccination Subjects with one Zoster Placebo Risk Difference or more event: Vaccine And 95% CI Injection-site AE 1604 (48.3%) 539 (16.6%) 31.7% (28.3%, 32.6%)* Erythema 1188 (35.8%) 227 (7.0%) 28.8% (26.9%, 30.6%)* Pain/Tenderness 1147 (34.5%) 278 (8.5%) 26.0% (24.1%, 27.9%)* Swelling 871 (26.2%) 147 (4.5%) 21.7% (20.1%, 23.4%)* Pruritus 237 (7.1%) 33 (1.0%) 6.1% (5.2%, 7.1%) * Warmth 57 (1.7%) 11 (0.3%) 1.4% (0.9%, 1.9%)* Hematoma 53 (1.6%) 46 (1.4%) 0.2% (-0.4%, 0.8%) Rash 10 (0.3%) 3 (0.1%) 0.2% (0.0%, 0.5%) * p<0.05 Oxman M et al. N Engl J Med. 2005;352:2271-2284; – Table 4 Safety: SAE – AE Substudy vs. Non- AE Substudy (Day of Vaccination to Day 42 Post-Vaccination) Subjects Zoster Placebo Risk Difference with one Vaccine and 95%CI or more n (%) n (%) SAE Whole Cohort 255 (1.37%) 254 (1.36%) 0.01% (-0.23%, 0.25%) AE Substudy 64 (1.92%) 41 (1.26%) 0.66% (0.05%, 1.28%)* Not in AE 191 (1.25%) 213 (1.38%) -0.13% (-0.39%, 0.12%) Substudy * P<0.05 Oxman M et al. N Engl J Med. 2005;352:2271-2284 Time to First Serious Adverse Event (SAE) from Day 0 Through Day 42 for the Entire Study Population The cumulative rates of SAE are shown for the time to the first SAE within Days 0-42 post-inoculation among all persons enrolled in the study. There is no significant treatment difference within age strata: Ages 60-69, p-value for log rank is 0.41, Ages 70 and older, p-value for log rank is 0.56. Overall treatment comparison: p-value for log rank is 0.94. Comparison of age strata 60-60 vs. ≥70: p-value for log-rank test is <0.0001. (Simberkoff et al. Annals Internal Medicine 2010; 152: 545-552.) Cumulative Mortality for the Entire Study Population Number at risk: Age 60-69: P 10223 10323 10245 7231 2081 ZV 10281 10331 10239 7223 2034 Age ≥ 70: P 8692 8775 8621 6337 1942 ZV 8713 8815 8646 6415 1948 Cumulative mortality rate is shown for the time to death among all persons enrolled in the study. There is no significant treatment difference within age strata: Ages 60-69, p-value for log rank is 0.20, Ages 70 and older, p-value for log rank is 0.37. Overall treatment comparison: p-value for log rank is 0.95. Comparison of age strata 60-60 vs. ≥70: p-value for log-rank test is <0.0001. (Simberkoff et al. Annals Internal Medicine 2010; 152: 545-552.) Zoster vaccine did not cause or induce shingles During the 30 days post vaccination: • 18 cases of shingles in the Placebo group versus only 6 cases in the Vaccine group • Vaccine virus DNA was not detected in any of 919 PCR-confirmed cases of shingles • All 919 were caused by wild-type VZV (Oxman MN et al. N Engl J Med 2005; 352:2271-2284.) Zoster Vaccine is Recommended for Immunocompetent Persons ≥ 60 Years of Age -------------------------------------------------------------------------------------------------- CDC. Recommended Adult Immunization Schedule – United States, 2010. MMWR 2010; 59(1). Safety and Efficacy of Zoster Vaccine in persons ≥80 years of age Rates of Serious Adverse Events (SAE) by COSTART Body System and Pathophysiologic Diagnostic Category Occurring During Days 0-42 Post-Inoculation Among Zoster Vaccine and Placebo Recipients in the Entire Study Population Zoster Vaccine Placebo (N=19,270) (N=19,276) Risk Difference (%) Vaccine- No. of No. (Percent) No. of No. P-Value SAE of Persons SAE (Percent) of Placebo with ≥1 SAE Persons (95% CI) with ≥1 SAE No. of Persons with 18,671 18,717 Safety Follow-up SAE among All 324 255 (1.37) 320 254 (1.36) 0.01 (-0.23, 0.25) 0.94 Persons By Age: 60 - 69 years§ 135 113 (1.12) 125 101 (1.00) 0.12 (-0.17, 0.40) 0.41 70 years or older§ 189 142 (1.66) 195 153 (1.78) -0.12 (-0.51, 0.27) 0.55 70 - 80 years§§ 150 115 (1.57) 165 132 (1.80) -0.23 (-0.65, 0.19) 0.28 80 years or older§§ 39 27 (2.24) 30 21 (1.64) 0.60 (-0.49, 1.74) 0.28 § A pre-specified age stratum and analysis §§ Not a pre-specified age stratum and not a pre-specified analysis (Simberkoff et al.
Load more

Recommended publications
  • Herpes Zoster: Postherpetic Neuralgia and Other Complications C
    Herpes Zoster: Postherpetic Neuralgia and Other Complications C. Peter N. Watson • Anne A. Gershon Michael N. Oxman Editors Herpes Zoster: Postherpetic Neuralgia and Other Complications Focus on Treatment and Prevention Editors C. Peter N. Watson Michael N. Oxman Department of Medicine Department of Medicine University of Toronto Division of Infectious Diseases Toronto, Ontario University of California Canada San Diego, La Jolla, California USA Anne A. Gershon College of Physicians and Surgeons Medicine Service Columbia University College Infectious Diseases Section of Physicians and Surgeons VA San Diego Healthcare System New York, NY San Diego, California USA USA ISBN 978-3-319-44346-1 ISBN 978-3-319-44348-5 (eBook) DOI 10.1007/978-3-319-44348-5 Library of Congress Control Number: 2017931063 © Springer International Publishing Switzerland 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Reviewarticle Looking Back on the Way to Develop a Live Vaccine Against Chickenpox and to Prevent Herpes Zoster: Current Status and Future Prospect
    ReviewArticle Looking Back on The Way to Develop a Live Vaccine Against Chickenpox and to Prevent Herpes Zoster: Current Status and Future Prospect Michiaki Takahashi, M.D., Ph.D.* *Prince Mahidol Award Laureate in Public Health in 2008 for development of vaccine to prevent chicken pox Emeritus Professor of Osaka University Director, The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Osaka, 565-0871 Japan Siriraj Med J 2013;65:58-68 E-journal: http://www.sirirajmedj.com . BACKGROUND OF DEVELOPMENT OF saged virus was lower at 39o than at 34o, whereas the titers OKA STRAIN OF LIVE VARICELLA VACCINE of the original strain virus were comparable at these two temperatures) and to be remarkably less-neurovirulent 1. ATTENUATION OF MEASLES VIRUS AND when inoculated into thalamus of monkeys, being com- I 1 POLIO VIRUS parable with Sabins’ attenuated Saukett’s strain ) (Table In 1959-1962, I worked on development of attenua- 1a, 1b, 1c). ted live measles vaccine in the laboratory of Professor In brief, this observation confirmed that viruses Yoshiomi Okuno, Research Institute for Microbial Diseases become readily attenuated by passage in chick embryo Osaka University. This Institute was established in 1934, cells less sensitive (foreign species cells) as compared being full of refreshed activities of young researchers, with which was passaged in sensitive cells. yielding world remarkable findings such as oxygenase by Dr. Osamu Hayaishi in Department of Biochemistry TABLE 1-A. Background of development of varicella vaccine and Cell fusion by Sendai Virus (Hemagglutination Virus (From Takahashi M, Hamada T, Okabe S. Biken J. 1963 Oct;6: of Japan, HVJ) by Dr.
    [Show full text]
  • Medical Term for Shingles Vaccine
    Medical Term For Shingles Vaccine Soporiferous Vernen teasels her pointings so reversely that Agamemnon disrespect very intermittently. Unreluctant Mahesh get-up her leanly.antibacchiuses so expressly that Oleg luxuriated very soothfastly. Unrighteous Garfinkel single-spaces, his usneas conceded entitled It offers and forehead or is one. It produces is shingles for? You may precede rash? National and death in vaccine for medical term, and they have no more important complications occur if an optimal experience shingles, but it is! What are symptoms get two vaccine for medical term used. Also requires two vaccines are also feel those not have milder and consult your skin infection that if you need to vzv vaccine for medical term. Genital herpes zoster after five treatments and risk for your immune system generating a vaccine for medical term for getting vaccinated. But people with age groups articles on to help with primary infection of zostavax while pregnant women may want to. Do about scratches to become milder symptoms are you for rheumatoid arthritis on another worry about vaccine before making a very dangerous to read brochures were offered. Get shingles vaccine, you follow are designed for several sensitivity can significantly increases as varicella zoster vaccine may. And has a rash appears as. Scarring is both physical trauma center for antibodies are available strategies that are apprehensive about vaccinations currently available zoster global survey were initially started. Myositis definition tetanus is often in immunocompromised hosts are sufficient for the product is essential to know why vaccinate or linger for? No medication is shedding of medical term association with medications, is surprising given early treatment? Get my mouth, vaccine for medical term.
    [Show full text]
  • Varicella-Zoster Virus
    Varicella-Zoster Virus John Vang 780 E. Ridge Rd. Salisbury, NC 28144 Clinical Laboratory Science, Junior Class Winston-Salem State University 601 S. Martin Luther King, Jr. Drive Winston-Salem, NC 27110 Varicella-Zoster Virus Introduction The human herpesvirus 3 (HHV-3) or known as the varicella-zoster virus (VZV), is a type of virus that belongs to the α-herpesvirus family.1 This virus is highly infectious and can cause varicella and herpes zoster (HZ), commonly known as chickenpox and shingles, respectively. Varicella affects mostly young children and adolescents; however, adults may be able to contract it as well.2 Due to the varicella vaccination, infections have declined in the United States and are much rarer. The Center for Disease Control (CDC) states that since the vaccination program began in 1995, there has been over a 90% decrease in varicella cases. Although with the varicella vaccination, it is still possible to be infected with the disease, however the symptoms will be milder. Once a person has been exposed to and recovered from varicella, the virus can remain inactive for many years or decades before reemerging as herpes zoster.3,4 HZ largely affects adults over the age of 50 that have had varicella at one point during childhood. The CDC reports that one in three adults will develop HZ during their lifetime. The risks and complications associated with getting HZ are directly proportional with age. Brief History The first documentation of VZV was described as a rash of unknown cause in many ancient civilization writings.5 In 1888, it was suggested that there was a correlation between HZ and varicella; it was not until the 1950s, that this correlation was proven correct.5,6 Ever since the correlation was made between varicella and HZ by Thomas Weller, a considerable amount of advancements have been made in the prevention and treatment of the diseases associated with VZV.
    [Show full text]
  • Extending National Immunization Programmes: the Case of Varicella Vaccination in the European Union
    Master’s Thesis Medical Anthropology and Sociology Graduate School of Social Sciences Extending national immunization programmes: The case of varicella vaccination in the European Union Victoria Szerényke Boehm Amsterdam, 7th August 2020 Student ID number: 12757152 Contact: [email protected] Supervisor: Dr. Stuart Blume Second reader: Dr. Danny de Vries Science appears calm and triumphant when it is completed; but science in the process of being done is only contradiction and torment, hope and disappointment. - Pierre Paul Émile Roux, French physician, bacteriologist, and immunologist and developer of the first effective treatment for diphtheria1 1 as cited in Plotkin, 2009 2 Abstract The idea that, like medicine, health policymaking should be evidence-based has gained wide popularity and support. This is also the case for immunization policies. Despite the claim that the decision to include new vaccines in national immunization programmes is rational and based on objective evidence, countries often react very differently to new vaccines. Against this background, the question arises how and why vaccines are introduced into immunization programmes. The case of varicella/chickenpox vaccination is peculiar in this respect. Even though it has been available for thirty years and a wide range of evidence is accessible and despite a trend towards harmonizing vaccination programmes in the European Union, countries reach different conclusions about the vaccine. Historical research on the introduction of vaccines suggests that in addition to evidence, politics, perceptions, as well as public and professional opinions influence immunization policymaking. Drawing from that, this thesis explores why and how vaccines are included in national immunization programmes through the case of varicella decision-making in Germany, the United Kingdom, and the Netherlands.
    [Show full text]
  • Varicella-Zoster Virus Infection: Natural History, Clinical Manifestations
    NEW MICROBIOLOGICA, 41, 2, 95-105, 2018, ISN 1121-7138 REVIEW Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies Giulia Freer1, Mauro Pistello1,2 1Retrovirus Center and Virology Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy; 2Virology Unit, Pisa University Hospital, Pisa, Italy SUMMARY Varicella-zoster virus (VZV) is the etiologic agent of varicella (chicken pox), a childhood exanthematic disease that develops as a result of primary infection, and zoster (shingles), caused by reactivation of the virus persisting in a latent form in the dorsal sensory ganglia. Although varicella is generally a mild self-limiting illness, in immunocompromised subjects and adults it can have a serious clinical course that can lead to permanent damage of the central nervous system. In these and in most zoster cases, treatment with anti-herpetic drugs and/or immunotherapy is necessary. Because it is highly contagious, varicella is one of the most common exanthematic diseases. It is prevent- able by vaccination with an attenuated vaccine administered around the first year of age, and with a boost vaccination in school age. This article briefly describes the natural history and pathophysiology of VZV infection and its current epidemiology and provides an overview of current and future vaccine options to protect against varicella and/or zoster. Received October 24, 2017 Accepted January 29, 2018 INTRODUCTION latency-related genes to reactivate those that lead to viral replication (Baines and Pellets 2007; Baird et al., 2013; Ger- Varicella-zoster virus (VZV) belongs to the Herpesviridae, shon et al., 2012; Kennedy et al., 2015; Zerboni et al., 2014).
    [Show full text]
  • Chapter 22: Varicella; Epidemiology and Prevention of Vaccine
    Varicella Adriana Lopez, MHS; Theresa Harrington, MD, MPH&TM; and Mona Marin, MD Varicella is an acute infectious disease caused by varicella- zoster virus (VZV). Primary varicella infection (chickenpox) Varicella was not reliably distinguished from smallpox until the end of ● Acute infectious disease caused the 19th century. In 1875, Rudolf Steiner demonstrated that by varicella-zoster virus (VZV) chickenpox was caused by an infectious agent by inoculating ● Distinguished from smallpox at volunteers with the vesicular fluid from a patient with acute the end of the 19th century varicella. In 1954, Thomas Weller used cell culture to isolate VZV from vesicular fluid of patients with varicella or zoster. A ● Live, attenuated varicella vaccine developed in 1970s live, attenuated varicella vaccine was developed in Japan in the 1970s. The vaccine virus was developed from virus isolated ● Varicella and MMRV vaccines by Michiaki Takahashi from vesicular fluid from an otherwise licensed for use in the U.S. in healthy child with varicella disease. Varicella vaccine was 1995 and 2005, respectively licensed for general use in Japan and Korea in 1988, and in the United States in 1995 for persons age 12 months or older. In 2005, a combination measles, mumps, rubella, and varicella (MMRV) vaccine was licensed in the United States for persons Varicella-Zoster Virus (VZV) age 12 months through 12 years. ● Herpesvirus (DNA) ● Primary infection results in varicella (chickenpox) Varicella-Zoster Virus ● Reactivation of latent infection VZV is a DNA virus and is a member of the herpesvirus results in herpes zoster group. Like other herpesviruses, VZV persists in the body as a (shingles) latent infection after the primary (first) infection; VZV persists ● Short survival in environment in sensory nerve ganglia.
    [Show full text]
  • TPWKY This Is Exactly Right
    TPWKY This is Exactly Right. Anonymous We were having hat day at school and I am not normally a hat person. I had this numb spot on my head all day long and it just was like a not scratchable itch. It was all day, all day, all day. But I thought, like at first I was like, 'Oh it's just hat day, I'm just not comfortable wearing this ridiculous Christmas tree hat at school.' (laughs) By the weekend, so that started midweek, by that weekend it had started to move down my forehead to like my eyebrow area and that's when it just became this burning, itchy, couldn't really make it go away thing. A few days went by, so this was all at Christmastime, that's when we were driving from where we lived in Buffalo down to my parents on Long Island. And that drive, my forehead felt like someone had a match to it. I think I kind of lucked out with shingles because it was a really small patch that I had but to feel like someone had a lighter on my forehead for as long as it did was just the craziest thing. I had no idea what it was though. So I started doing the WebMD thing and I was searching for like 'what's a large red spot', 'red spot with blisters' because it started to get these really small spots over time. And that's kind of when I started to see other pictures of people who had the same thing and people were saying it's shingles, it's shingles, it's shingles.
    [Show full text]
  • Varicella-Zoster Virus
    Varicella-Zoster Virus Virology and Clinical Management Edited by Ann M. Arvin Stanford University School of Medicine and Anne A. Gershon Columbia University College of Physicians and Surgeons Published in association with the VZV Research Foundation The Pitt Building, Trumpington Street, Cambridge, United Kingdom The Edinburgh Building, Cambridge CB2 2RU, UK 40 West 20th Street, New York, NY 10011–4211, USA 10 Stamford Road, Oakleigh, VIC 3166, Australia Ruiz de Alarcón 13, 28014 Madrid, Spain Dock House, The Waterfront, Cape Town 8001, South Africa http://www.cambridge.org © Cambridge University Press 2000 This book is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published 2000 Printed in the United Kingdom at the University Press, Cambridge Typeface Minion 10.5/14pt System QuarkXPress™ [] A catalogue record for this book is available from the British Library Library of Congress Cataloguing in Publication data Varicella-zoster virus : virology and clinical management / edited by Ann Arvin and Anne Gershon p. cm. “Published in association with VZV Research Foundation.” Includes index. ISBN 0 521 66024 6 (hardback) 1. Chickenpox. 2. Shingles (Disease) 3. Varicella-zoster virus. I. Arvin, Ann M. II. Gershon, Anne A. III. VZV Research Foundation. [DNLM: 1. Herpesvirus 3, Human–pathogenicity. 2. Chickenpox–epidemiology. 3. Chickenpox–therapy. 4. Herpes Zoster–epidemiology. 5. Herpes Zoster–therapy. QW 165.5.H3 V299 2000] RC125.V375 2000 616.9′14–dc21 00-023915 ISBN 0 521 66024 6 hardback Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication.
    [Show full text]
  • The Development of Vaccines: How the Past Led to the Future
    PERSPECTIVES In the last decade of the nineteenth TIMELINE century, vaccine development started to have a rationale. The science was produced The development of vaccines: by workers in Great Britain, Germany, the United States and Pasteur’s laboratory in how the past led to the future France. The key developments were methods to inactivate whole bacteria, which could then be used as vaccines, the discovery of Stanley A. Plotkin and Susan L. Plotkin bacterial toxins, the production of antitoxins Abstract | The history of vaccine development has seen many accomplishments, and the realization that immune serum con- tained substances (antibodies) that neutral- but there are still many diseases that are difficult to target, and new technologies ized toxins or bacterial replication. Daniel are being brought to bear on them. Past successes have been largely due to Salmon and Theobald Smith were the first to elicitation of protective antibodies based on predictions made from the study of inactivate bacteria, and wrote: “Immunity is animal models, natural infections and seroepidemiology. Those predictions have the result of exposure of … the animal body often been correct, as indicated by the decline of many infections for which to the chemical products of the growth of specific microbes which constitute the virus vaccines have been made over the past 200 years. of contagious fever.” (REF. 17.) Furthermore, during the last years of the nineteenth It is said that only those who have seen the complexions of milkmaids and inferred that century and the beginning of the twentieth, beginning of things can understand the cowpox protected them from the ravages of inactivated whole-cell vaccines against present.
    [Show full text]
  • Herpes Zoster: Postherpetic Neuralgia and Other Complications Focus on Treatment and Prevention 2017 Herpes Zoster: Postherpetic Neuralgia and Other Complications C
    C. Peter N. Watson Anne A. Gershon Michael N. Oxman Editors Herpes Zoster: Postherpetic Neuralgia and Other Complications Focus on Treatment and Prevention 2017 Herpes Zoster: Postherpetic Neuralgia and Other Complications C. Peter N. Watson • Anne A. Gershon Michael N. Oxman Editors Herpes Zoster: Postherpetic Neuralgia and Other Complications Focus on Treatment and Prevention Editors C. Peter N. Watson Michael N. Oxman Department of Medicine Department of Medicine University of Toronto Division of Infectious Diseases Toronto, Ontario University of California Canada San Diego, La Jolla, California USA Anne A. Gershon College of Physicians and Surgeons Medicine Service Columbia University College Infectious Diseases Section of Physicians and Surgeons VA San Diego Healthcare System New York, NY San Diego, California USA USA ISBN 978-3-319-44346-1 ISBN 978-3-319-44348-5 (eBook) DOI 10.1007/978-3-319-44348-5 Library of Congress Control Number: 2017931063 © Springer International Publishing Switzerland 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.
    [Show full text]
  • Fact Book 2012
    VACCINE FACT BOOK 2012 Preface “Prevention is better than cure” is a proverb in many other languages as well. This idea is central to the development of vaccines, which have transformed human health since the time of Edward Jenner in the late 18th Century. Smallpox has been eradicated, polio largely controlled and measles and rubella have been targeted for elimination. Bacterial meningitis is becoming rare in countries that vaccinate their children. Acquisition of hepatitis B at birth can now be prevented. All of this and more has been accomplished by the development and deployment of vaccines. Most of these advances occurred in the last 50 years. More and more vaccines are being developed and brought into use. Japanese scientists have contributed to the recent creation of powerful vaccines, notably against pertussis and chickenpox. These two vaccines are used throughout the world. It is, therefore, fitting that Japan also takes advantage of other new vaccines such as rotavirus, pneumococcal conjugates and human papillomavirus, which can, respectively, prevent infantile diarrhea and dehydration, invasive infections and pneumonia, and various forms of cancer, particularly cancer of the cervix in women. Japanese children and adults should share in the benefits of vaccination. Moreover, governments have a reason to promote vaccination: better health of a general population lowers medical costs and is associated with broad economic benefits. Therefore, the vaccine industry has been growing in importance and in many countries, including Japan, governments consider vaccine production as a precious resource, for example, to control epidemics of new types of influenza and other emerging infections. New techniques and strategies of vaccine development are being constantly discovered and it is likely there will be more diseases that can be prevented.
    [Show full text]